Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer

Stefano Greggi, M. Giovanna Salerno, Giuseppe D'Agostino, Gabriella Ferrandina, Domenica Lorusso, Luigi Manzione, Salvatore Mancuso, Giovanni Scambia

Research output: Contribution to journalArticle

Abstract

24 Patients were enrolled into a phase I-II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2-7). Topotecan was administered on days 1-5 by 30 min i.v. infusion immediately after gemcitabine given by 30 min i.v. on days 1 and 3; cycles were repeated every 28 days. The starting doses were topotecan 0.7 mg/m2 and gemcitabine 200 mg/m2. Following dose levels were 08/400; 0.9/600; 0.9/800 for topotecan and gemcitabine, respectively. The maximum tolerated dose (MTD) was reached at dose level 3, the dose-limiting toxicity being represented by febrile neutropenia and thrombocytopenia. After the MTD was reached, granulocyte-colony-stimulating factor was administered in 27% of cycles. Mild and manageable was non hematological toxicity. All patients are so far evaluable for response. Among them 2 complete responses (8.3%; 95% Cl: 2.6-19), 1 partial response (4.2%; 95% Cl: 3.8-12), 9 no change (37.5%; 95% Cl: 18-56.8) and 12 progressions (50%; 95% Cl: 30-70) have been registered. Based on these data, there is no evidence that combining topotecan and gemcitabine is better than using either of the two drugs used separately.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalOncology
Volume60
Issue number1
DOIs
Publication statusPublished - 2001

    Fingerprint

Keywords

  • Gemcitabine
  • Ovarian cancer
  • Phase I-II
  • Topotecan

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Greggi, S., Salerno, M. G., D'Agostino, G., Ferrandina, G., Lorusso, D., Manzione, L., Mancuso, S., & Scambia, G. (2001). Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology, 60(1), 19-23. https://doi.org/10.1159/000055291